Pavel P. Potapov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pavel P. Potapov has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Mikhail Yu. Brovko
Sechenov First Moscow State Medical University (Sechenov University)
7 shared publications - Victoria I. Sholomova
Sechenov First Moscow State Medical University (Sechenov University)
7 shared publications - Larisa A. Akulkina
Sechenov First Moscow State Medical University (Sechenov University)
6 shared publications - Sergey V. Moiseev
Sechenov First Moscow State Medical University (Sechenov University); Lomonosov Moscow State University
6 shared publications - Anastasia A. Shchepalina
Sechenov First Moscow State Medical University (Sechenov University)
5 shared publications - Aram A. Kitbalian
Sechenov First Moscow State Medical University (Sechenov University); Lomonosov Moscow State University
4 shared publications
Latest Publications
- Open Access
- 15 October 2025
- Published by Sechenov University in National Health Care (Russia)
- Vol. 6 (3) , 46-57
Export of Russian medical education: challenges and prospects
Global competition for human recourses significantly increases the importance of education exports, including for Russia. The national development goals include increasing the number of foreign students up to 500,000 by 2030. Aim. To analyze the dynamics of the number of foreign medical students at Russian universities, with a perspective up to 2030, and to provide proposals for approaches to increasing the number of foreign students. Materials and methods. Data on the admission, number and graduation of foreign medical students were obtained from the federal statistical form “Information on the organization carrying out educational activities in higher education programs” posted on the website of the Ministry of Science and Higher Education of Russia. Statistical processing methods were used to analyze the data; forecasts were obtained using simple exponential smoothing methods. Results. The total number of students in medical specialties in 2024 showed an increase, amounting to 79,709 and 6740 people for extra-budgetary and budgetary forms of education funding, which corresponded to 24 % and 14 % of foreigners in all areas of training. Taking into account current admission rates and the average length of study in medical specialties, the estimated number of international students in medical programs may reach 140–142 thousand people by 2030 (excluding quota students). This indicator can be significantly influenced by the number of students who are expelled during their studies (up to 33 % in some specialties), which requires definite attention. Conclusion. Foreign citizens are interested in medical education in Russia, but to ensure sustainable growth during the period from 2025 to 2030, it is necessary to implement a comprehensive strategy aimed at increasing the attractiveness and competitiveness of Russian medical education, as well as creating favorable conditions for foreign students.
- 15 October 2025
- Published by Sechenov University in National Health Care (Russia)
- Vol. 6 (3) , 46-57
Open AccessExport of Russian medical education: challenges and prospects
Global competition for human recourses significantly increases the importance of education exports, including for Russia. The national development goals include increasing the number of foreign students up to 500,000 by 2030. Aim. To analyze the dynamics of the number of foreign medical students at Russian universities, with a perspective up to 2030, and to provide proposals for approaches to increasing the number of foreign students. Materials and methods. Data on the admission, number and graduation of foreign medical students were obtained from the federal statistical form “Information on the organization carrying out educational activities in higher education programs” posted on the website of the Ministry of Science and Higher Education of Russia. Statistical processing methods were used to analyze the data; forecasts were obtained using simple exponential smoothing methods. Results. The total number of students in medical specialties in 2024 showed an increase, amounting to 79,709 and 6740 people for extra-budgetary and budgetary forms of education funding, which corresponded to 24 % and 14 % of foreigners in all areas of training. Taking into account current admission rates and the average length of study in medical specialties, the estimated number of international students in medical programs may reach 140–142 thousand people by 2030 (excluding quota students). This indicator can be significantly influenced by the number of students who are expelled during their studies (up to 33 % in some specialties), which requires definite attention. Conclusion. Foreign citizens are interested in medical education in Russia, but to ensure sustainable growth during the period from 2025 to 2030, it is necessary to implement a comprehensive strategy aimed at increasing the attractiveness and competitiveness of Russian medical education, as well as creating favorable conditions for foreign students.
- Open Access
- 15 March 2023
- Published by Sechenov University in Sechenov Medical Journal
- Vol. 13 (4) , 33-44-44
Angiopoietin-1 as a marker of endothelial dysfunction and a risk factor for acute kidney injury in patients with COVID-19: retrospective cohort study
Recently, data have been published on the leading role of endothelial dysfunction in the development of severe COVID-19, including acute renal failure (AKI) and poor prognosis in this group of patients.Aim. To define the role of angiopoetin-1(Ang-1) as a marker of endothelial dysfunction in development of AKI in patients, hospitalized with COVID-19.Materials and methods. 76 patients with confirmed coronavirus infection were included in the study. AKI was diagnosed according to KDIGO 2012 criteria in 44 patients (group 1), 32 patients without sings of kidney disfunction were in group 2. Beside standard clinical and laboratory markers on admission we evaluated serum Ang-1 level with ELISA. We used regression analysis for AKI risk factors evaluation, we calculated odds ratio (OR) and 95% confidence intervals (CI). We used Cox regression for evaluation of risk of death.Results. The serum level of angiopoietin-1 was significantly higher in patients with COVID-19 with AKI: 1.8 (1.5; 2.1) ng/ml vs 1.58 (1.29; 1.7) ng/ml in group 2, р < 0.01. In deceased patients, the level of Ang-1 at admission was significantly higher than in patients who was discharged: 1.91 (1.71; 2.32) ng/ml vs 1.58 (1.34; 1.67) ng/ml, respectively, p = 0.0001. In unifactorial regression analysis we confirmed, that increase of serum Ang-1 level >1.66 ng/ml on admission is the risk factor for AKI development in patients with COVID-19 (OR 5.7, 95% CI 1.7–19.1, р < 0.01). In Cox regression development of AKI increased the absolute risk of death: Hazard ratio = 5.159 (95% CI 1.839–14.469), p = 0.002.Conclusion. The high serum level of Ang-1 in patients with COVID-19 at hospital admission is the marker of systemic endothelial dysfunction and the risk factor for AKI and poor prognosis.
- 15 March 2023
- Published by Sechenov University in Sechenov Medical Journal
- Vol. 13 (4) , 33-44-44
Open AccessAngiopoietin-1 as a marker of endothelial dysfunction and a risk factor for acute kidney injury in patients with COVID-19: retrospective cohort study
Recently, data have been published on the leading role of endothelial dysfunction in the development of severe COVID-19, including acute renal failure (AKI) and poor prognosis in this group of patients.Aim. To define the role of angiopoetin-1(Ang-1) as a marker of endothelial dysfunction in development of AKI in patients, hospitalized with COVID-19.Materials and methods. 76 patients with confirmed coronavirus infection were included in the study. AKI was diagnosed according to KDIGO 2012 criteria in 44 patients (group 1), 32 patients without sings of kidney disfunction were in group 2. Beside standard clinical and laboratory markers on admission we evaluated serum Ang-1 level with ELISA. We used regression analysis for AKI risk factors evaluation, we calculated odds ratio (OR) and 95% confidence intervals (CI). We used Cox regression for evaluation of risk of death.Results. The serum level of angiopoietin-1 was significantly higher in patients with COVID-19 with AKI: 1.8 (1.5; 2.1) ng/ml vs 1.58 (1.29; 1.7) ng/ml in group 2, р < 0.01. In deceased patients, the level of Ang-1 at admission was significantly higher than in patients who was discharged: 1.91 (1.71; 2.32) ng/ml vs 1.58 (1.34; 1.67) ng/ml, respectively, p = 0.0001. In unifactorial regression analysis we confirmed, that increase of serum Ang-1 level >1.66 ng/ml on admission is the risk factor for AKI development in patients with COVID-19 (OR 5.7, 95% CI 1.7–19.1, р < 0.01). In Cox regression development of AKI increased the absolute risk of death: Hazard ratio = 5.159 (95% CI 1.839–14.469), p = 0.002.Conclusion. The high serum level of Ang-1 in patients with COVID-19 at hospital admission is the marker of systemic endothelial dysfunction and the risk factor for AKI and poor prognosis.
- Open Access
- 21 September 2022
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 32 (5) , 763-769-769
A case of severe COVID-19 in a patient with progressive fibrosing interstitial lung disease
Interstitial lung diseases (ILDs) is a wide group of diffuse parenchymal lung diseases that can lead to interstitial pulmonary fibrosis. Clinical course of all ILDs, in particular with chronic fibrosing phenotype, can be complicated by an acute exacerbation caused by infection. Today, data about clinical course of COVID-19 in patients with progressive interstitial lung diseases is limited. In this case we described the course of COVID-19 infection in a patient with an interstitial pneumonia with autoimmune features (IPAF) and a progressive pulmonary fibrosis (PPF). We also discussed the typical features of COVID-19 in this population and the directions for further research.
- 21 September 2022
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 32 (5) , 763-769-769
Open AccessA case of severe COVID-19 in a patient with progressive fibrosing interstitial lung disease
Interstitial lung diseases (ILDs) is a wide group of diffuse parenchymal lung diseases that can lead to interstitial pulmonary fibrosis. Clinical course of all ILDs, in particular with chronic fibrosing phenotype, can be complicated by an acute exacerbation caused by infection. Today, data about clinical course of COVID-19 in patients with progressive interstitial lung diseases is limited. In this case we described the course of COVID-19 infection in a patient with an interstitial pneumonia with autoimmune features (IPAF) and a progressive pulmonary fibrosis (PPF). We also discussed the typical features of COVID-19 in this population and the directions for further research.
- Open Access
- 4 August 2022
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (6) , 743-747
Risk factors of kidney injury in patients with COVID-19
Aim. To determine the incidence and risk factors of acute kidney injury (AKI) in Russian cohort of patients with COVID-19. Materials and methods. We included 315 patients, who were hospitalized with COVID-19 from October 2020 till February 2021. The diagnosis was established on the basis of the positive SARS-CoV-2 swab test and/or typical radiologic findings on CT scans. Results. AKI complicated the clinical course in 92 (29.21%) cases. The independent risk factors of AKI were female sex, underline chronic kidney disease and the highest level of C-reactive protein during hospitalization. In the general group of patients were 41 (13%) lethal cases, in the group with AKI 32 (34.8%). Compared with those without AKI, patients with AKI had 4.065 (95% confidence interval 2.154 to 7.671) times the odds of death. Respiratory support, the highest serum creatinine and glucose levels appeared to be the risk factors of death among patients with AKI in the multivariable Cox regression. Conclusion. The clinical course of COVID-19 was complicated by AKI in 29% cases. The independent risk factors of AKI in patients with COVID-19 are underline chronic kidney disease, circulatory disorder and the highest level of C-reactive protein during hospitalization.
- 4 August 2022
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (6) , 743-747
Open AccessRisk factors of kidney injury in patients with COVID-19
Aim. To determine the incidence and risk factors of acute kidney injury (AKI) in Russian cohort of patients with COVID-19. Materials and methods. We included 315 patients, who were hospitalized with COVID-19 from October 2020 till February 2021. The diagnosis was established on the basis of the positive SARS-CoV-2 swab test and/or typical radiologic findings on CT scans. Results. AKI complicated the clinical course in 92 (29.21%) cases. The independent risk factors of AKI were female sex, underline chronic kidney disease and the highest level of C-reactive protein during hospitalization. In the general group of patients were 41 (13%) lethal cases, in the group with AKI 32 (34.8%). Compared with those without AKI, patients with AKI had 4.065 (95% confidence interval 2.154 to 7.671) times the odds of death. Respiratory support, the highest serum creatinine and glucose levels appeared to be the risk factors of death among patients with AKI in the multivariable Cox regression. Conclusion. The clinical course of COVID-19 was complicated by AKI in 29% cases. The independent risk factors of AKI in patients with COVID-19 are underline chronic kidney disease, circulatory disorder and the highest level of C-reactive protein during hospitalization.
- Open Access
- 26 May 2022
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (4) , 497-502
Organizing pneumonia as a pulmonary manifestation of post-COVID syndrome: features of diagnosis and treatment
Treatment of patients with long-term persistent symptoms after COVID-19 is an urgent problem for clinicians around the world. One of the most significant manifestations of post-COVID-19 syndrome is organizing pneumonia that is usually treat with corticosteroids. The paper presents a clinical case of typical course of post-COVID-19 organizing pneumonia in a patient without previous lung disease. Risk factors, diagnostic methods and treatment options in this group of patients are also discuss.
- 26 May 2022
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (4) , 497-502
Open AccessOrganizing pneumonia as a pulmonary manifestation of post-COVID syndrome: features of diagnosis and treatment
Treatment of patients with long-term persistent symptoms after COVID-19 is an urgent problem for clinicians around the world. One of the most significant manifestations of post-COVID-19 syndrome is organizing pneumonia that is usually treat with corticosteroids. The paper presents a clinical case of typical course of post-COVID-19 organizing pneumonia in a patient without previous lung disease. Risk factors, diagnostic methods and treatment options in this group of patients are also discuss.
- Open Access
- 6 July 2021
- Published by Wiley
Tofacitinib versus standard of care treatment in patients with COVID-19: a multicenter non-randomized controlled study
This non-randomized controlled study aimed to assess the efficacy of tofacitinib in reducing the risk of invasive mechanical ventilation or death in patients with COVID-19. Patients with COVID-19 associated with reduced oxygen saturation, increased C-reactive protein (≥50 mg/L), and/or persisting fever were recruited. Tofacitinib was administered in addition to standard of care therapy. Study outcomes were evaluated separately in the groups of patients with oxygen saturation at rest ≤93% and >93%. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated using Cox regression analysis adjusted for inverse propensity score weighting. Overall, 384 patients with COVID-19 (212 males; median age 60 years) were included in our study and were treated with tofactinib (n=131) or standard of care alone (n=253). The percentages of patients who started mechanical ventilation or died during hospitalization in the tofacitinib and control groups were 12.5% (9/72) vs. 14.1% (26/185) among patients who required respiratory support (HR 0.92, 95% CI 0.33-2.56), and 1.7% (1/59) vs. 4.4% (3/68) in those with normal oxygen saturation (HR 0.83; 95 CI 0.07-9.44). Tofacitinib did not reduce the risk of invasive mechanical ventilation or death in patients with COVID-19, although the analysis of these outcomes favored tofacitinib.
- 6 July 2021
- Published by Wiley
Open AccessTofacitinib versus standard of care treatment in patients with COVID-19: a multicenter non-randomized controlled study
This non-randomized controlled study aimed to assess the efficacy of tofacitinib in reducing the risk of invasive mechanical ventilation or death in patients with COVID-19. Patients with COVID-19 associated with reduced oxygen saturation, increased C-reactive protein (≥50 mg/L), and/or persisting fever were recruited. Tofacitinib was administered in addition to standard of care therapy. Study outcomes were evaluated separately in the groups of patients with oxygen saturation at rest ≤93% and >93%. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated using Cox regression analysis adjusted for inverse propensity score weighting. Overall, 384 patients with COVID-19 (212 males; median age 60 years) were included in our study and were treated with tofactinib (n=131) or standard of care alone (n=253). The percentages of patients who started mechanical ventilation or died during hospitalization in the tofacitinib and control groups were 12.5% (9/72) vs. 14.1% (26/185) among patients who required respiratory support (HR 0.92, 95% CI 0.33-2.56), and 1.7% (1/59) vs. 4.4% (3/68) in those with normal oxygen saturation (HR 0.83; 95 CI 0.07-9.44). Tofacitinib did not reduce the risk of invasive mechanical ventilation or death in patients with COVID-19, although the analysis of these outcomes favored tofacitinib.
- Open Access
- 15 November 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (11) , 17-23
Risk factors for the early development of septic shock in patients with severe COVID-19
Aim. In a retrospective study, we evaluated factors associated with the early development of septic shock in patients with severe COVID-19. Materials and methods. We collected medical records of the intensive care unit patients submitted by the local COVID-19 hospitals across Russia to the Federal Center for the Critical Care at the Sechenov First Moscow State Medical University (Sechenov University). Septic shock in crticially ill patients requiring mechanical ventilation was defined as a need in vasopressors to maintain blood pressure. Results. We studied 1078 patients with severe COVID-19 who were admitted to the intensive care units for respiratory support. There were 611 males and 467 females. The mean age was 61.013.7 years. Five hundred twenty five medical records (48.7%) were received from the Moscow hospitals, 159 (14.7%) from the Moscow region, and 394 (36.5%) from the hospitals located in 58 regions of the Russian Federation. In 613 (56.9%) patients, diagnosis of SARS-CoV-2 infection was confirmed by PCR, and in the other cases it was established on the basis of the clinical picture and the results of the chest CT scan. Septic shock developed in 214 (19.9%) of 1078 patients. In the logistic regression model, the risk of septic shock in patients older than 50 years was higher than in patients of a younger age (OR 2.34; 95% CI 1.533.67; p0.0001). In patients with more severe SARS-CoV-2 infection, there was an increase in the prevalence of cardiovascular diseases, including coronary heart disease and atrial fibrillation, type 2 diabetes and malignant tumors. The risk of septic shock in patients with three or more concomitant diseases was higher than in patients without any concomitant chronic diseases (OR 1.76; 95% CI 1.762.70). Conclusion. The risk of septic shock in patients with acute respiratory distress syndrome induced by SARS-CoV-2 is higher in patients older than 50 years with concomitant diseases, although a severe course of the disease is also possible in younger patients without any concomitant disorders.
- 15 November 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (11) , 17-23
Open AccessRisk factors for the early development of septic shock in patients with severe COVID-19
Aim. In a retrospective study, we evaluated factors associated with the early development of septic shock in patients with severe COVID-19. Materials and methods. We collected medical records of the intensive care unit patients submitted by the local COVID-19 hospitals across Russia to the Federal Center for the Critical Care at the Sechenov First Moscow State Medical University (Sechenov University). Septic shock in crticially ill patients requiring mechanical ventilation was defined as a need in vasopressors to maintain blood pressure. Results. We studied 1078 patients with severe COVID-19 who were admitted to the intensive care units for respiratory support. There were 611 males and 467 females. The mean age was 61.013.7 years. Five hundred twenty five medical records (48.7%) were received from the Moscow hospitals, 159 (14.7%) from the Moscow region, and 394 (36.5%) from the hospitals located in 58 regions of the Russian Federation. In 613 (56.9%) patients, diagnosis of SARS-CoV-2 infection was confirmed by PCR, and in the other cases it was established on the basis of the clinical picture and the results of the chest CT scan. Septic shock developed in 214 (19.9%) of 1078 patients. In the logistic regression model, the risk of septic shock in patients older than 50 years was higher than in patients of a younger age (OR 2.34; 95% CI 1.533.67; p0.0001). In patients with more severe SARS-CoV-2 infection, there was an increase in the prevalence of cardiovascular diseases, including coronary heart disease and atrial fibrillation, type 2 diabetes and malignant tumors. The risk of septic shock in patients with three or more concomitant diseases was higher than in patients without any concomitant chronic diseases (OR 1.76; 95% CI 1.762.70). Conclusion. The risk of septic shock in patients with acute respiratory distress syndrome induced by SARS-CoV-2 is higher in patients older than 50 years with concomitant diseases, although a severe course of the disease is also possible in younger patients without any concomitant disorders.
- Open Access
- 15 November 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (11) , 117-121
Visceral leishmaniasis: a challenging diagnosis in internal medicine
Leishmaniasis is a vector-born parasitic disease characterized by predominant cutaneous or visceral involvement with fever, hepatosplenomegaly and anemia. Leishmaniasis has relatively high prevalence in tropical and subtropical areas. Several sporadic and mostly imported cases are detected in Russian Federation. Nevertheless, some local incidents are noted in southern areas (Crimea, Dagestan). Lack of epidemiological alertness hampers confirmation of diagnosis and may lead to incorrect treatment. The article summarizes current state of knowledge in epidemiology, diagnostic approach and treatment of leishmaniasis. Particular clinical case is discussed.
- 15 November 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (11) , 117-121
Open AccessVisceral leishmaniasis: a challenging diagnosis in internal medicine
Leishmaniasis is a vector-born parasitic disease characterized by predominant cutaneous or visceral involvement with fever, hepatosplenomegaly and anemia. Leishmaniasis has relatively high prevalence in tropical and subtropical areas. Several sporadic and mostly imported cases are detected in Russian Federation. Nevertheless, some local incidents are noted in southern areas (Crimea, Dagestan). Lack of epidemiological alertness hampers confirmation of diagnosis and may lead to incorrect treatment. The article summarizes current state of knowledge in epidemiology, diagnostic approach and treatment of leishmaniasis. Particular clinical case is discussed.